In summary, the overexpression of ABC transporters (MRP1/ABCC1, BRCP/ABCG2, and IAP) and survivin at the de novo diagnosis of DLBCL is associated with relapsed and primary refractory disease and an increased risk of R-CHOP treatment resistance. Here, ABCC1 is linked to diffuse large B-cell lymphoma.